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The clinical application of advanced next-generation sequencing technologies is increasingly 
uncovering novel classes of mutations that may serve as potential targets for precision medicine 
therapeutics. Here, we show that a deep intronic splice defect in the COL6A1 gene, originally 
discovered by applying muscle RNA sequencing in patients with clinical findings of collagen 
VI–related dystrophy (COL6-RD), inserts an in-frame pseudoexon into COL6A1 mRNA, encodes 
a mutant collagen α1(VI) protein that exerts a dominant-negative effect on collagen VI matrix 
assembly, and provides a unique opportunity for splice-correction approaches aimed at restoring 
normal gene expression. Using splice-modulating antisense oligomers, we efficiently skipped 
the pseudoexon in patient-derived fibroblast cultures and restored a wild-type matrix. Similarly, 
we used CRISPR/Cas9 to precisely delete an intronic sequence containing the pseudoexon and 
efficiently abolish its inclusion while preserving wild-type splicing. Considering that this splice 
defect is emerging as one of the single most frequent mutations in COL6-RD, the design of specific 
and effective splice-correction therapies offers a promising path for clinical translation.
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Introduction
Collagen VI–related dystrophies (COL6-RDs) are extracellular matrix disorders, affecting skeletal 
muscle and connective tissues and ranging in phenotypic severity from the severe Ullrich congenital 
muscular dystrophy (UCMD), through intermediate phenotypes, to the milder Bethlem myopathy 
(reviewed in ref. 1). Clinical manifestations include muscle weakness, distal joint hyperlaxity, prox-
imal joint contractures, scoliosis, and progressive respiratory insufficiency. COL6-RDs are among 
the most common congenital muscular dystrophy subtypes (1–4), and while supportive interventions 
such as nocturnal noninvasive ventilation have improved survival considerably (5, 6), there are no 
specific therapeutic interventions.
Collagen type VI synthesis, secretion, and assembly in the extracellular space is a complex, step-
wise process mediated by the collagen-synthesizing tissue-resident fibroblast populations (7, 8). The 3 
major disease-related COL6 genes (COL6A1, COL6A2, and COL6A3) encode 3 polypeptide chains [α1(VI), 
α2(VI), and α3(VI)] that are necessary for collagen VI production. Each of  the 3 chains is composed of  
a short central collagenous triple helical domain, distinguishable by the presence of  uninterrupted Gly-
X-Y repeats, that is flanked by globular domains. The triple helical domains enable the α1(VI), α2(VI), 
and α3(VI) chains to intertwine and form a heterotrimeric α1-α2-α3 monomer. Monomers join laterally 
to form staggered antiparallel dimers, which then associate in parallel to form a 112-nm-long tetramer. 
The tetramers are subsequently secreted into the extracellular space where they form higher-order struc-
tures by end-to-end association and branching (9–14). Functional collagen VI is a connected meshwork 
of  tetramers, ultrastructurally appearing as beaded microfibrils (15).
Mutations in COL6A1, COL6A2, and COL6A3 cause COL6-RD and act in a recessive or dominant 
fashion, with de novo dominant-negative mutations emerging as the most prevalent mutation type 
across the phenotypic spectrum (1, 16–19). These mutations are in-frame exon skipping mutations or 
glycine missense mutations in the triple helical Gly-X-Y motifs and occur preferentially at the N-termi-
nal end of  the respective triple helical domains (14, 16, 20, 21). Formation of  the triple helix compris-
ing the 3 α chains proceeds from the C- to the N-terminal end; therefore, chains carrying a mutation 
located towards their N-terminus can result in a helix stable enough to retain the mutant chain in the 
α1-α2-α3 monomer. If  monomers incorporating a mutant chain are then carried forward to reach the 
tetrameric state, 15 out of  16 nascent tetramers contain at least one mutant chain, resulting in perva-
sive disturbance of  collagen VI matrix assembly and function (14, 16).
Recently, as part of  a large study exploring the utility of  muscle RNA sequencing as a diagnostic tool 
in neuromuscular disorders, we uncovered an in-frame pseudoexon retention in COL6A1 that mapped at 
the N-terminal end of  the triple helical domain of  the α1(VI) chain, in 4 unrelated patients with a clinical 
and pathological phenotype highly suggestive of  COL6-RD (22). Parallel whole-genome sequencing in 
all 4 patients identified a de novo heterozygous deep intronic variant (c.930+189C>T, hereafter referred 
as +189C>T) creating the donor splice site activating the pseudoexon insertion (22). Our initial screen-
ing for the +189C>T mutation in international COL6-RD cohorts resulted in the identification of  27 
additional patients harboring the +189C>T mutation (22), thus revealing +189C>T as an unexpectedly 
common causative mutation for COL6-RD.
Mutations activating pseudoexons such as the one described here are excellent targets for 
splice-correction interventions. In particular, the skipping of  pathogenic pseudoexons by anti-
sense-mediated oligomers has been validated in cultured patient-derived cells in a wide range of  clin-
ical scenarios, to rescue loss-of-function mutations (23–29). Splice-modulating antisense oligomers 
are short, single-stranded, chemically modified oligonucleotides, rationally designed to specifically 
recognize and hybridize to precursor messenger RNA (pre-mRNA) through Watson-Crick base pair-
ing, and consequently interfere with steps of  its maturation, such as splicing. Phosphorodiamidate 
morpholino oligomers (PMOs) and 2′-O-methyl–modified bases on a phosphorothioate backbone 
(2′OMe) are 2 antisense chemistries developed to increase oligomer stability and affinity, and both 
have been successfully used to promote exon skipping in vitro and in vivo (30–32). Considering that 
2 splice-modulating therapeutic antisense oligomers have been recently approved by the US Food & 
Drug Administration (FDA), namely a PMO for treating a subset of  Duchenne muscular dystrophy 
patients carrying deletions for which the antisense therapy restores the reading frame after dystro-
phin (DMD) exon 51 skipping (33, 34), and a 2′-O-methoxyethyl (MOE) phosphorothioate oligo-
mer for spinal muscular atrophy that promotes inclusion of  SMN2 exon 7 (35, 36), developing this 
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approach for COL6-RD has high translational potential. In the case of  this dominantly acting muta-
tion and in contrast to Duchenne muscular dystrophy, successful pseudoexon skipping results in nor-
mal transcripts from the mutant allele, with the potential to fully restore normal COL6A1 expression.
Recently, gene editing via the clustered regularly interspaced short palindromic repeats (CRISPR)/
CRISPR-associated protein 9 (Cas9) system has also been exploited to address exon skipping. In this sys-
tem, a single RNA molecule (guide RNA or gRNA) recruits an endonuclease (Cas9) to a specific genomic 
locus to induce a double-stranded break, provided that a protospacer-adjacent motif  (PAM) is present adja-
cent to the targeted site. Following cleavage, gDNA is repaired either through homology-directed repair, or, 
if  no template DNA is present to carry out homology-directed repair, through a nonhomologous end-join-
ing process that is prone to introducing random insertion/deletion mutations (indels) at the site of  repair 
(37). Skipping of  exons by CRISPR/Cas9 can be accomplished using a dual-gRNA strategy, where target-
ing each flanking intron of  the exon to be spliced out with a gRNA leads to the genomic excision of  the 
targeted exon and its exclusion from the final mRNA product. This approach has been successfully used to 
reframe several deletion and truncating mutations in the DMD gene, where deleting up to 11 additional con-
secutive exons allowed the restoration of  the reading frame and expression of  a partially functional internal-
ly deleted dystrophin (38–44). Furthermore, deep intronic mutations are especially amenable to dual-gRNA 
excision strategies in the case of  pathogenic recessive (45, 46) or dominantly acting mutations, as small 
deletions in introns are predicted to mostly spare the normal splicing patterns within the targeted gene.
Here, we further extend the cohort of  COL6A1 +189C>T mutation–positive patients who we find 
present with an unusually progressive clinical course. We investigate the functional consequences of  the 
+189C>T mutation for splicing and show that the mutant α1 chain carrying the pseudoexon sequence is 
translated and secreted, interfering with collagen VI matrix assembly. We identify specific splice-modulat-
ing oligomers capable of  effectively skipping the abnormal splicing product induced by this mutation and 
restoring a wild-type (WT) matrix phenotype in cultured cells. We show that deleting an intronic fragment 
encompassing the site of  the deep intronic splice-activating mutation along with the pseudoexon sequence 
efficiently restores normal splicing from the mutant allele without affecting the normal allele.
Results
Screening for the COL6A1 +189C>T mutation. In Cummings et al. (22), we initially reported a pseudoex-
on insertion in RNA sequencing reads from muscle specimens of  4 index patients (US1, US2, UK1, 
and UK2; corresponding to N31, N32, N29, and N30, respectively; see ref. 22) with clinical pheno-
types and muscle imaging highly suggestive of  COL6-RD, muscle immunohistochemical findings of  
mislocalized collagen VI (Figure 1A), and who were previously negative for directed COL6 mutation 
testing and whole-exome sequencing. The splice-gain event inserts a 72-nt pseudoexonic sequence 
between COL6A1 exons 11 and 12 (22) (Figure 1B). Subsequent whole-genome sequencing showed 
that all 4 patients carried a de novo deep intronic heterozygous change at the pseudoexon junction 
(NM_001848 c.930+189C>T; Figure 1C) (22). This COL6A1 +189C>T mutation is predicted to cre-
ate a consensus site for the pseudoexon 5′ splice donor (SD) site (aggc>AGgt), and thus to trigger its 
insertion, using a cryptic signal located upstream as splice acceptor (SA) site (agAC, Figure 1D). Pres-
ence of  the 72-nt pseudoexon inclusion was verified by reverse transcription PCR (RT-PCR) in both 
muscle specimens and cultured dermal fibroblasts of  patients (22), and was further verified by Sanger 
sequencing (Supplemental Figure 1; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.124403DS1). See complete unedited blots in the supplemental material.
Since our initial identification of  the COL6A1 +189C>T mutation, we sought to determine whether 
it constitutes a recurrent mutational mechanism in COL6-RD. We screened mutation-negative COL6-
RD–like patients using targeted genomic DNA sequencing, and identified 31 additional cases harboring 
the COL6A1 +189C>T mutation (27 of  whom were reported in Cummings et al., ref. 22; Supplemental 
Table 1). Consistent with findings in the 4 index cases, the mutation arose de novo in all cases in which 
segregation could be verified (20 of  20 families screened, Figure 1C).
Clinical manifestations associated with the COL6A1 +189C>T mutation. Upon review of  early clinical man-
ifestations and timing of  first concerns for the 35 cases, it was notable that there was a relative paucity of  
prominent neonatal symptoms in most patients (Supplemental Table 1), which contrasts with the classical 
UCMD phenotype (1, 47–49). Patients with the COL6A1 +189C>T mutation, however, uniformly pro-
gressed in severity to match typical UCMD, with loss of  ambulation and full-time wheelchair use on aver-
4insight.jci.org   https://doi.org/10.1172/jci.insight.124403
R E S E A R C H  A R T I C L E
5insight.jci.org   https://doi.org/10.1172/jci.insight.124403
R E S E A R C H  A R T I C L E
age by the age of  9 years (3–14 years), respiratory insufficiency requiring nocturnal noninvasive ventilation 
starting on average at the age of  13 years (7–21 years), scoliosis, and development of  proximal contractures 
while maintaining distal joint hypermobility (Supplemental Figure 2 and Supplemental Table 1). Thus, the 
accelerating evolution of  the disease in COL6A1 +189C>T patients from relatively few clinical findings in 
the neonatal period to a typically severe UCMD phenotype suggests a strong dominant-negative mecha-
nism of  action, which appears to be more pronounced even when compared with other dominantly acting 
mutations in the COL6 genes. Immunohistofluorescence performed on muscle biopsy sections revealed 
a lack of  colocalization of  collagen VI immunoreactivity to the basement membrane (Figure 1A), as is 
typically seen in COL6-RD patients with dominant-negative mutations (14).
Splicing profile of  the COL6A1 +189C>T mutation. We established a functional splicing assay in 
HEK293T cells expressing splicing reporter (minigene) constructs that harbored either the C (reference) 
or the T (mutant) allele, and analyzed the splicing profiles by RT-PCR (Figure 1E). The constructs har-
bored no variant other than the +189C>T, as verified by Sanger sequencing, such that any variation in 
splicing can be attributed to the mutation. While the +189C>T indeed created a 5′SD and prompted 
a splice-gain event in the minigenes encompassing exons 11 to 13 (Ex-11-13) and exons 10 to 13 (Ex-
10-13) (Figure 1E), the pseudoexon 3′SA site (that defines the 72-nt insertion) was not utilized in this 
system. Rather, the natural 3′SA of  exon 11 was used, resulting in a 187-nt insertion (115 nt of  intron 11 
sequence plus 72 nt of  pseudoexon sequence), as verified by sequencing the gel-extracted PCR fragments. 
In contrast, the construct carrying intron 11 sequence only (IVS-11) did not produce any splice gain (Fig-
ure 1E). Notably, minigenes harboring the T allele in addition returned normally spliced products as the 
most abundant splicing outcome (Figure 1E). Together these data validate that the +189C>T mutation 
is responsible for the pseudoexon insertion, but suggest that the mutation is leaky. In addition, these data 
suggest that the factors contributing to the pseudoexon 3′SA recognition are not sufficiently present in 
the exogenously expressed minigenes and may include additional cis elements stabilizing the 3′SA further 
upstream or downstream, or additional splicing factors not present in HEK293T cells.
We then quantified pseudoexon inclusion in various available specimens, including cultured dermal 
fibroblasts. Dermal fibroblasts are readily accessible, can be expanded in culture, and express high levels 
of  the 3 main COL6 genes, and thus serve as a valid model to study COL6-RD in vitro (7). The pseudo-
exon percent spliced in (PSI), calculated using the RNA sequencing data (50), was on average 26.0% of  
total COL6A1 in muscle specimens (19.7%–32.0%, n = 4), but only 9.0% for one corresponding cultured 
dermal fibroblast sample (Figure 1, B and F), lower than the 50% expected in the context of  heterozy-
gosity without mosaicism (Figure 1C). Using endpoint RT-PCR, we similarly observed lower-than-ex-
pected pseudoexon expression in muscle specimens (39.8%–48.5%, Figure 1G), with again lower levels 
in cultured dermal fibroblasts (10.8%–18.8%, Figure 1G and Supplemental Figure 3). In one patient 
(F1) for whom muscle-derived fibroblasts were available, the pseudoexon expression was notably lower 
in cultured muscle-derived fibroblasts (9.8%), than in the fresh muscle specimen (27.5%) (Figure 1H). 
Together, these data suggest that the process of  growing primary cells in vitro alters the splicing efficiency 
of  this pseudoexon, or favors cells capable of  splicing it out.
Figure 1. A deep intronic COL6A1 mutation creates a donor splice site, prompting the insertion of a pseudoexonic sequence. (A) Immunofluores-
cence images of muscle biopsy sections of patient US1 and one unaffected control costained for collagen VI (red), basement membrane marker laminin 
(green), and with nuclear stain DAPI (blue). Scale bars: 50 μm. (B) Sashimi plots comparing skeletal muscle biopsy (top) and cultured dermal fibroblast 
(bottom) RNA sequencing reads from patient UK1, at the COL6A1 intron 11 locus. (C) Genomic DNA chromatograms for the COL6A1 +189C>T mutation 
testing in family US2. (D) Schematics of the COL6A1 +189C>T mutation locus depicting the pseudoexon sequence boundaries, and splicing outcomes. 
Splice-modulating antisense oligomers targeting the pseudoexon pre-mRNA sequence are used to promote its skipping as a therapeutic strategy. 
(E) Splicing reporter (minigene) constructs were prepared by subcloning various segments of COL6A1 genomic DNA (intervening sequence 11 [IVS-11], 
exons 11 to 13 [Ex-11-13], or exons 10 to 13 [Ex-10-13]) into the pET01 vector (top). Minigenes were transfected into HEK293T cells, and RNA was isolated 
24 hours later. Electrophoretic gel image (bottom) represents reverse transcription PCR (RT-PCR) products, amplified using pET01 primers (arrows). 
Composition of the amplicons is exemplified for Ex-10-13 (right). L = molecular weight ladder. Gel representative of 3 transfections. (F) The pseudoexon 
percent spliced in (PSI) index was calculated from the RNA sequencing data of 4 muscle specimens and 1 dermis-derived cultured fibroblast specimen, 
and indicates the percentage of COL6A1 transcript reads that include the pseudoexon. (G and H) Detection of the 72-nucleotide pseudoexon expression 
in 3 cultured dermal fibroblasts and their corresponding muscle biopsy specimens (G), or in patient F1’s muscle biopsy, cultured dermis- and muscle-de-
rived fibroblasts (H), using RT-PCR. Primers spanning COL6A1 exons 10 to 20 (G), or exons 10 to 15 (H) were used for amplification. RT-PCR gel images 
were quantified by densitometry (ImageJ) to determine the percentage pseudoexon expression (% p-exon, indicated below each lane and representing 
the average of 3 to 4 gel quantifications). (I) Location of the single-nucleotide polymorphism rs1980982 relative to the +189C>T mutation site. cDNA 
from US14 fibroblasts, in whom the “T” allele of rs1980982 is located in cis to the +189T mutation (below), was amplified with primers located in exons 
10 and 19 (arrows) for subsequent shotgun cloning.
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To determine the splicing outcomes of  the pre-mRNA transcribed from the mutant allele only, 
we first identified one patient (US14) carrying an exonic polymorphism (rs1980982 T>C) in close 
proximity to the pseudoexon inclusion site (Figure 1I), in whom the rs1980982 T allele and the +189T 
alleles were in phase with the +189T mutation. Shotgun cloning of  US14 dermal fibroblast–derived 
RT-PCR products, followed by sequencing of  individual colonies, indicated that 2 mRNA species were 
produced in similar abundance from the +189T allele in these fibroblasts, that either included the pseu-
doexon or did not (Supplemental Table 2). Next, careful examination of  RT-PCR gel electrophoresis 
from muscle-derived samples suggested the presence of  an additional splice variant of  higher molecu-
lar weight (Figure 1G, visible in the muscle US2 lane). Upon shotgun cloning and sequencing of  US2 
muscle–derived RT-PCR products, we identified a third splice product, of  low abundance, in which the 
mutant 5′SD was utilized in combination with the natural 3′SA of  the preceding exon 11 (Figure 1D), 
similar to the splice-gain products identified in the splicing reporter assays (Figure 1E). This splice 
variant encodes a premature termination codon. In summary, 3 distinct mRNA species originate from 
pre-mRNA transcripts harboring the mutant +189T allele: a normally spliced variant, an in-frame 
(72 bp) pseudoexon-containing variant, and, as a rare event in muscle tissue, an out-of-frame intronic 
insertion likely subject to mRNA decay (Figure 1D).
Effect of  the pseudoexon peptide insertion on collagen VI matrix assembly. The pseudoexon peptide, if  
translated, interrupts the Gly-X-Y repeats with a noncollagenous 24–amino acid sequence at the N-ter-
minal end of  the triple helical domain of  the α1(VI) chain (Figure 2A), the region in which most of  
the dominant-negative mutations causing COL6-RD reside (16, 17, 20, 21). To detect expression and 
secretion of  the pseudoexon peptide, we immunoprecipitated collagen VI from dermal fibroblast cell 
medium (secreted fraction) and lysates (cellular fraction), size-selected the protein fractions (by gel-ex-
tracting proteins within the 117–171 kDa range), and performed liquid chromatography–tandem mass 
spectrometry analysis. When using trypsin as the digestion enzyme, we confidently detected a peptide 
(RPLHLEGQGQPPR) that was unique to the patient sample (US8), and that was identified in both 
the cellular and secreted fractions (Table 1 and Supplemental Figure 4). The sequence of  this peptide 
corresponds to a fragment of  the predicted translated pseudoexon (Figure 2A). When using chymo-
trypsin, we similarly detected an overlapping peptide (HLEGQGQPPRHPA) in the patient cellular 
fraction (Table 1), while we did not detect any mutant peptide in the secreted fraction (possibly due to 
relatively low specificity of  the chymotrypsin digestion).
Using the predicted pseudoexon sequence, we produced an immunizing peptide and raised a poly-
clonal antibody [Pex11-α1(VI)] against the translated pseudoexon. On denaturing and reducing immu-
noblots, this pseudoexon-specific antibody detected a strong distinctive band in US8 and IR1 cellular 
and secreted fractions, at the approximate size for α1(VI) collagen (~130 kDa), while no band of  this 
molecular weight was detected in Ctrl1 fractions, or when probing with the preimmune sera (Figure 2B). 
Membranes that were first probed with Pex11-α1(VI), then stripped and reprobed with an α1(VI) collagen 
antibody, confirmed that the Pex11-α1(VI) signal corresponded to the same molecular weight as α1(VI) 
collagen (Figure 2C). Moreover, the posttranslational modifications that increase the molecular weight 
of  the α1(VI) collagen chain in the secreted fraction seem unaffected by the presence of  the pseudoexon 
(Figure 2C). Together with the mass spectrometry data, the pseudoexon-specific immunoblot detection 
in both intracellular and secreted fractions provides evidence that the mutant α1(VI) chain (containing 
the pseudoexonic peptide) is expressed and secreted.
Using negative-staining electron microscopy of  secreted proteins, we measured the microfibrillar 
length (calculated as the number of  tetramers per continuous microfibril), which was significant-
ly lower in patients’ samples compared with the normal sample (Figure 2D). Visual assessment of  
immunostaining images also revealed morphological differences in the collagen VI microfibril archi-
tecture, which appeared discontinuous and kinked (Figure 2E). Taken together, these observations 
point to a dominant-negative effect of  the mutant pseudoexon on collagen VI matrix assembly.
Skipping of  the COL6A1 pseudoexon with antisense oligomers. To direct splicing outcomes from the COL6A1 
+189T–transcribed pre-mRNA in favor of  normal transcripts, we first devised a pseudoexon-skipping strat-
egy using antisense oligomers (Figure 1D). We designed PMO and 2′OMe antisense oligomers targeting 
either the splice junctions (SA or SD) or pseudoexon internal sites (PEX) (Figure 3A, Supplemental Figure 
5A, and Supplemental Table 3), and based sequence design on thermophysical properties (GC content 
between 40% and 60%, avoidance of  C or G stretches, absence of  self-hybridization) (51, 52). We first 
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screened the series of  oligomers in the mutant pET-Ex-11-13–expressing HEK293T cells, and used as an 
assessment the ratio of  expression of  the pseudoexon-included over the WT products. Pseudoexon/WT 
ratios decreased with increasing oligomer concentration, for all PMO and 2′OMe oligomer treatments, 
with the exceptions of  2′OMe-SD1 and 2′OMe-SD2 for which ratios remained stable (Figure 3B and Sup-
plemental Figure 5B). Of the 4 PEX-targeting PMOs (PMO-PEX1 to -PEX4), PMO-PEX1 and -PEX2 low-
Figure 2. The COL6A1 pseudoexon is translated and exerts a dominant-negative effect on collagen VI matrix assembly in cultured dermal fibroblasts. (A) 
Schematic representing the exon composition of the triple helical domains’ N-terminal ends for each of the 3 α chains of collagen VI, including the predicted 
pseudoexon peptide sequence (shown in red) inserted between exons 11 and 12 of the α1 chain. The positions of the cysteine residues critical for dimer and 
tetramer stabilization are indicated for each chain. (B) A polyclonal antibody [Pex11-α1(VI)] was raised against the pseudoexon peptide, and used to probe a 
denaturing and reducing immunoblot of cell lysate (cellular, C) and media (secreted, S) protein extracts from cultured dermal fibroblasts of 2 patients and 
1 unaffected individual. Probing with the preimmune sera is shown (right). (C) An immunoblot prepared as described in B was probed with the Pex11-α1(VI) 
antibody (left), then stripped and probed with an antibody detecting α1(VI) collagen [α1(VI)-C] (right). (D) Dermal fibroblasts were cultured in the presence of 
L-ascorbic acid, and medium was collected to measure collagen VI microfibrillar length using rotary shadowing electron microscopy (EM). Representative nega-
tive-staining EM images showing isolated collagen VI microfibrils (13 to 44 microfibrils were imaged per sample). Scale bars: 200 nm. The collagen VI microfibril-
lar length (number of tetramers per microfibril) is reported as a dot plot (below), where lines represent mean ± standard deviation. *P < 0.001 by Mann-Whitney 
U test, Bonferroni corrected for 2 comparisons. (E) Dermal fibroblasts from 1 unaffected individual, 1 patient carrying the glycine substitution COL6A1 G290R, 
and 2 +189C>T patients were cultured for 3 days in the presence of L-ascorbic acid, and then cells were fixed and immunostained for matrix-deposited collagen 
VI (green) and with the nuclear stain DAPI (blue). Scale bars: 25 μm.
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ered pseudoexon/WT ratios with superior efficacy (Figure 3B). Because the PMOs tested showed activity 
with this splicing reporter, and because the PMO chemistry has an excellent safety profile and is currently in 
several phase 3 clinical trials, we selected PMO-SA, -SD, -PEX1, and -PEX2 for the following experiments.
To test antisense oligomers in the context of  their endogenous target, we treated 3 patient-derived der-
mal fibroblast lines, and used endpoint and quantitative RT-PCR assays to measure the relative levels of  
pseudoexon expression. Single treatments with the selected PMOs successfully suppressed pseudoexon 
inclusion in a dose-dependent manner (from 2.5 to 30 μM, Figure 3C). At the highest concentration test-
ed, PMO-SA, -PEX1, -PEX2, and -SD suppressed relative pseudoexon levels down to 0.54, 0.136, 0.157, 
and 0.426, respectively, compared with nontargeting-treated (PMO-NT–treated) cells (relative expression 
of  0.971, Figure 3D). Remarkably, among the series of  PMOs that we tested, those targeting PEX sequenc-
es were more effective than those directly targeting the mutant SD site. Similar superior effectiveness of  
targeting exonic splicing enhancer sites, or sites closer to the SA, as opposed to the splice sites, has been 
reported in other exon-skipping studies (discussed in ref. 52). This could indicate either that the mutant SD 
target sequence is difficult to access for the antisense oligomers because of  the pre-mRNA tertiary structure 
and/or that binding of  splicing enhancer factors at the pseudoexon site greatly contribute to its inclusion. 
In parallel, we measured total COL6A1 expression levels by quantitative RT-PCR, and found that they 
remained stable (Figure 3E), which was consistent with redirection of  splicing being the main mechanism 
for pseudoexon suppression, rather than mRNA knockdown.
We assessed whether combining nonoverlapping antisense oligomers into a single treatment could increase 
pseudoexon-skipping efficiency. We tested the 2 most effective compounds, PMO-PEX1 and PMO-PEX2, 
each in combination with PMO-SD. Treating cells with either combination skipped the pseudoexon with only 
slightly higher efficiency than each PMO separately at the comparative individual concentration (Figure 3F). 
For example, at 15 μM, treatment with PMO-PEX2 or with PMO-SD reduced pseudoexon expression levels 
down to 0.172 and 0.569, respectively. When combined in a single treatment of 30 μM total, PMO-PEX2 and 
PMO-SD reduced pseudoexon levels to 0.116, comparable to a single treatment with PMO-PEX2 at 30 μM.
Next, we sought to determine whether pseudoexon skipping, mediated either by PMO-PEX1 alone or 
by a combination of  PMO-PEX2 and PMO-SD, correlated with reduced expression of  the mutant-pseu-
doexon-containing collagen α1(VI) chain and with improved matrix deposition. We collected medium 
(secreted) and cell lysate (cellular) fractions from patients’ fibroblasts treated with PMOs, and proceed-
ed to immunoblotting using either a collagen α1(VI) antibody or the pseudoexon-specific antibody. We 
observed a marked decrease of  the mutant protein expression together with stable total collagen α1(VI) 
levels following either treatment, in both the cellular and the secreted fractions (Figure 4A). Furthermore, 
we found that these PMO treatments improved collagen VI matrix morphology in culture, by increasing 
the deposition of  thicker, longer, and continuous microfibrils, in 3 cell lines tested, as observed by immu-
nofluorescence (Figure 4B). Consistent with these observations, using negative-staining electron micros-
copy, we found that treatment with the PMO-PEX2 and PMO-SD combination significantly increased 
collagen VI continuous microfibrillar length in one patient cell line (R1), resulting in a higher number 
of  tetramers per microfibrils in the oligomer-treated compared with the nontargeting-PMO-treated and 
Table 1. Detection of the collagen α1(VI) pseudoexon peptide in cultured dermal fibroblasts with liquid chromatography–tandem 
mass spectrometry
Enzyme Dermal fibroblast ID Fraction Mascot score of α1 type VI collagen Pseudoexon detection
Peptide sequence Peptide m/z value
Trypsin
Ctrl1
Cellular 2,095 N/A N/A
Secreted 1,486 N/A N/A
US8
Cellular 1,494 RPLHLEGQGQPPR 495.61 (z = 3) 742.91 (z = 2)
Secreted 1,308 RPLHLEGQGQPPR 742.91 (z = 2)
Chymotrypsin
Ctrl1
Cellular 1,283 N/A N/A
Secreted 918 N/A N/A
US8
Cellular 949 HLEGQGQPPRHPA 475.24 (z = 3) 712.36 (z = 2)
Secreted 1,095 N/A N/A
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untreated samples (Figure 4C). Unexpectedly, PMO treatment also significantly increased collagen VI 
microfibrillar length in an unaffected control sample, although at a lower P value (Figure 4C). Altogether, 
these results demonstrate that the PMOs selected in this study are potent effectors of  pseudoexon skip-
ping, which in turn abrogates the pseudoexon load and improves collagen VI matrix morphology.
Figure 3. PMOs efficiently skip the COL6A1 pseudoexon. (A) Location of the phosphorodiamidate morpholino antisense oligomers (PMOs) targeting the 
splice acceptor (SA), the splice donor (SD), or sequences within the pseudoexon (PEX). Asterisks in PMO-SA, PMO-PEX3, and PMO-PEX4 denote the pres-
ence of a mismatch between the oligomer sequence and the target sequence. (B) HEK293T cells expressing the minigene construct Ex-11-13 were trans-
fected with each PMO oligomer at the indicated concentrations, and RNA was isolated 48 hours later. Electrophoretic gels of RT-PCR products amplified 
as in Figure 1E are shown (top), representative of 3 transfection replicates. PCR fragment densities were quantified from the gel images using ImageJ, to 
determine the ratio of pseudoexon over normal (pseudoexon/WT) products for each lane. Graph (bottom) reports the pseudoexon/WT ratios from 3 repli-
cate treatments. Lines represent the average of the technical replicates ± standard deviation. PMO-NT = nontargeting PMO. Mock = transfection reagent 
only. (C) RT-PCR detection of the pseudoexon expression in patient IR1 cultured dermal fibroblasts following a 48-hour treatment with selected PMOs 
is shown as an example. (D–F) Relative gene expression in patient-derived cultured dermal fibroblasts treated for 48 hours with PMOs at the indicated 
concentrations, measured by quantitative RT-PCR assays specific for the pseudoexon (D and F) or for total COL6A1 (E). Expression levels were normalized 
to the housekeeping gene PGK1 and measured as relative to the corresponding mock-treated fibroblasts. Each data point represents the average of 2 to 
3 treatments on 1 biological replicate, and lines represent the average of the 3 biological replicates (patients R1, IR1, and CA1). Repeated-measures 2-way 
ANOVA with Bonferroni’s multiple comparisons test was applied. #P < 0.05 for all concentrations on the graph; *P < 0.05 for the indicated concentration.
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Correction of  the COL6A1 pseudoexon mis-splicing using CRISPR/Cas9. We next devised a therapeutic strat-
egy that could lead to permanent correction of  the splice defect through gene editing. We used a dual-gR-
NA system to induce an intronic deletion encompassing the pseudoexon sequence along with the site of  
the mutation to restore normal expression from the mutant allele. This strategy would not be allele specific, 
but we surmised that because the cuts are deep in the intron (93 bp from exon 11 and 282 bp from exon 12) 
it would not affect processing of  the intron allowing for normal splicing of  both alleles. We designed a pair 
of  gRNAs (annotated upstream 1 or U1, and downstream 1 or D1) flanking the pseudoexon sequence for 
Figure 4. Skipping of the COL6A1 pseudoexon mitigates the dominant-negative effect in cultured dermal fibroblasts. Cultured dermal fibroblasts 
from controls and patients were treated with the nontargeting control PMO (PMO-NT), or with PMO-PEX1, or a combination of PMO-PEX2 and PMO-SD, 
at a total PMO concentration of 30 μM for each condition, in the presence of L-ascorbic acid, for 4 days. (A) Immunoblots of the medium (secreted) 
or cell lysate (cellular) fractions were probed with the pseudoexon-specific antibody [Pex11-α1(VI)], and then blots were stripped and probed with an 
antibody detecting collagen α1(VI). Tubulin was probed as control. Mock = transfection reagent only. (B) Fibroblast cultures were fixed and stained for 
matrix-deposited collagen VI (green). Nuclei were stained with DAPI (blue). Scale bars: 25 μm. (C) Microfibrillar length (number of tetramers per collagen 
VI microfibril) was measured as described in Figure 2D, and is reported as a dot plot. Lines represent mean ± standard deviation. *P < 0.05, **P < 0.0002 
by Mann-Whitney U test, Bonferroni corrected for 2 comparisons.
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a predicted 103-bp deletion (Figure 5A). We first transfected into HEK293T cells a pSpCas9BB-2A-GFP 
dual-guide-expressing plasmid carrying both gRNAs, and enriched cells for GFP expression by fluores-
cence-activated flow cytometry, to validate dual-gRNA excision potential at the target region (Figure 5B). 
Next, we tested the efficacy of  this dual-gRNA approach to skip the pseudoexon in the splicing reporter 
assay (Ex-10-13). Amplification of  the minigene cDNA showed successful skipping of  the splice-gain prod-
uct from the +189T construct, and no change in expression from the +189C construct (Figure 5C).
Next, we nucleofected patient-derived fibroblasts with 10 μg of  the pSpCas9BB-2A-GFP dual-guide 
plasmid, enriched cells for GFP expression, and on genomic DNA amplification detected a truncated 
fragment corresponding to 79.2% of  total PCR products (43.5% when transfecting 5 μg of  plasmid, Fig-
ure 5D), suggesting high efficiency of  Cas9 cutting and DNA repair by excision. We quantified pseudoex-
on expression in the transfected IR1 fibroblasts by endpoint RT-PCR and found it to be reduced relative 
to fibroblasts transfected with the control plasmid (Figure 5E). The reduced pseudoexon expression again 
corresponded to a marked reduction of  the mutant chain production (Figure 5F). Importantly, in control 
and in patient-derived transfected cells, total α1(VI) collagen production remained unchanged (Figure 
5F), suggesting that the intronic deletion does not affect expression of  the normal allele.
Discussion
Deep intronic variants that alter splicing are frequently inaccessible with exon-based diagnostic sequencing 
approaches. The recent incorporation of RNA sequencing and whole-genome sequencing into the diag-
nostic workflow for mutation-negative patients, however, has revealed such variants as an important class 
of disease-causing mutations (22). This is exemplified by our discovery of a de novo COL6A1 deep intronic 
mutation (c.930+189C>T) (22), that we now report in a large cohort of 35 independent COL6-RD patients.
The discovery of  this deep intronic COL6A1 +189C>T mutation sheds light on a previously unrecog-
nized mutational mechanism for COL6-RD: in-frame pseudoexonic insertion. In our cohort of  35 unrelat-
ed COL6-RD patients, we found this mechanism to be associated with an invariably severe UCMD pheno-
type, albeit with a seemingly delayed clinical presentation of  symptoms compared with typical UCMD (1, 
5, 18). The reasons for this delay and subsequent accelerated progression of  symptoms in patients with this 
COL6A1 +189C>T mutation are not yet clear and may be directly related to this particular COL6 mutational 
mechanism, either due to (a) incomplete penetrance of  the pseudoexon splice sites (mutant splice donor 
and cryptic splice acceptor), which causes the pseudoexon-inserted transcripts to be diluted out, and could 
be subject to temporal regulation; or (b) build-up of  a dominant-negative, or toxic, mode of  action carried 
out by the mutant-peptide-containing α1 chain; or both. An important consideration is that the pseudoex-
on encodes a noncollagenous peptide with potentially unique disruptive properties that is located at the 
N-terminal end of  the triple helical domain, beyond the cysteine residue crucial for dimer stabilization, a 
location that enables the classical dominantly acting mutations mentioned above to be carried forward into 
the higher-order molecular structures of  collagen VI. In this study, we provide evidence using mass spec-
trometry and immunoblotting with an antibody specific for the pseudoexon that the pseudoexon-containing 
α1(VI) chain is translated and secreted. Immunoblotting with an α1(VI) collagen antibody suggested that 
posttranslational processing of  the α1(VI) chains (containing the pseudoexon or not) was seemingly similar. 
By immunofluorescence, however, we showed that the pseudoexon interferes with collagen VI matrix for-
mation in culture, and leads to collagen VI mislocalization in muscle tissue. Intriguingly, interference with 
matrix formation is observed even when relatively low levels of  the pseudoexon are spliced in, as is seen 
in dermal fibroblast cultures. One explanation is that the dominant-negative effect of  the mutant α1 chain 
containing the pseudoexon peptide is amplified by its incorporation into the high-molecular-order collagen 
VI matrix assembly. The hampered end-to-end association of  tetramers into beaded microfibrils and the 
irregular matrix formation we observed are consistent with such a mechanism. Moreover, the pseudoexon 
encodes a peptide sequence rich with positively charged residues (7 of  24) and likely adopts a misfold-
ed structure interrupting the collagenous triple helical domain that could potentially not only inactivate 
tetramers but also initiate pathological and/or toxic interactions with other components in the matrix.
The discovery of  the COL6A1 +189C>T mutation immediately presented the opportunity to use 
rationally designed antisense therapies to promote exon skipping (or pseudoexon skipping) of  this aber-
rant splice event, as potential interventions in COL6-RD patients carrying this mutation. The most prom-
ising option currently is the application of  splice-modulating antisense oligomers. Successful advances 
in this technology are exemplified by the approval of  2 splice-modulating drugs by the FDA in the past 2 
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years (33, 36), including one designed to skip exon 51 of  the DMD gene, as the first FDA-approved drug 
indicated for Duchenne muscular dystrophy, which has set a precedent for a regulatory pathway for this 
class of  drugs. In contrast to Duchenne muscular dystrophy, in which the exon-skipping strategy is used 
to convert severe out-of-frame transcripts into in-frame and partially functional transcripts (similar to the 
internal deletion of  alleles that results in the milder Becker muscular dystrophy), the pseudoexon-skip-
ping approach explored here should have an even greater molecular benefit, as each event of  successful 
skipping will generate a normal COL6A1 mRNA. Similar to what has been observed when specifically 
knocking down dominant COL6 mutations with the goal of  converting to haploinsufficiency (53–56), 
suppressing the dominant-negative pseudoexon correlated with improved collagen VI matrix properties. 
For example, treatment with a combination of  2 PMO oligomers (PMO-PEX2 and PMO-SD) correlated 
with a marked reduction in detection of  the mutant chain by the Pex11-α1(VI) antibody, improved col-
lagen VI microfibril morphology, and increased collagen VI microfibrillar length. These results suggest 
that despite what must be a strong dominant-negative effect of  this particular mutation, reducing its 
Figure 5. Cas9/dual-gRNA targeted genomic excision of the +189C>T mutation corrects the COL6A1 pseudoexon splicing defect. (A) Schematic 
depicting position of the 2 gRNAs (gRNA upstream 1, U1; and downstream 1, D1) that were designed to excise a 103-nucleotide fragment harboring 
the pseudoexon-generating mutation from the deep intronic region of COL6A1 intron 11. gRNA-U1 and -D1 were subcloned into a Cas9-GFP plasmid 
(Cas9+U1D1) harboring 2 gRNA cassettes for dual gRNA expression. (B) Amplification of genomic DNA from HEK293T cells transfected with 5 μg of the 
Cas9+U1D1 plasmid and GFP-enriched by cell sorting 48 hours after transfection. (C) HEK293T cells cotransfected with 1 μg of each splicing reporter 
(+189C, WT; +189T, mutant), and 5 μg of the Cas9+U1D1 plasmid, and sorted after 48 hours to enrich for GFP expression, were assessed for pseudoexon 
splicing by RT-PCR. (D) Amplification of genomic DNA from human patient fibroblast cell line IR1, 48 hours after nucleofection with 5 or 10 μg of the 
Cas9+U1D1 plasmid (GFP-sorted). (E) IR1 patient fibroblasts were nucleofected with 10 μg of Cas9+U1D1 plasmid, and sorted for GFP expression after 48 
hours, before RNA isolation. Expression of the pseudoexon was assessed by endpoint RT-PCR. (F) US8 patient fibroblasts were nucleofected with 10 μg 
of Cas9+U1D1, followed by GFP enrichment, and cell lysates were harvested for immunoblotting. Membranes were probed with a pseudoexon-specific 
antibody [Pex11α1(VI)] and a housekeeping control (α-tubulin), or with an antibody assaying total collagen α1 (VI) expression [α1(VI)-C] and α-tubulin.
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expression improves matrix structure and has the potential to rescue collagen VI function. Our previously 
published observation of  a substantial amelioration of  clinical severity in patients with somatic mosa-
icism for other, typically severe, dominantly acting COL6 mutations supports this assumption, as in such 
patients the dominant mutation load is diminished by virtue of  the mosaicism (57).
Antisense oligomers would require lifelong repeat infusions to maintain activity. In contrast, gene 
editing would provide the potential for permanent correction after a single administration via a variety 
of  possible in vivo delivery options. Here, we employed a dual-gRNA system to excise the pseudoexon 
sequence and were able to achieve a high excision efficiency in patient fibroblasts (up to 79.2%). This cor-
related with reduction of  the pseudoexon inclusion and significant reduction of  resulting mutant collagen 
α1(VI) chain. Even though the deep intronic excision approach does not discriminate between the WT and 
mutant alleles, it does not affect the expression and normal splicing from the WT allele, as determined by 
the total collagen VI α1 levels detected through immunoblotting in the control as well as in the patient cell 
lines treated with Cas9 and dual gRNAs. Translating this approach to the clinic is attractive, as the col-
lagen VI–producing muscle interstitial cells are proliferative, meaning that genomic corrections would be 
transmitted to the cell progeny. Also, considering that collagen VI is a secreted protein that can extend into 
the extracellular space further away from its site of  production, this mitigates the need for correction of  
all fibroblasts. While each of  these 2 therapeutic strategies (antisense-mediated skipping and gene editing) 
possesses their advantages and disadvantages, the oligomer approach will be translatable to the clinic earli-
er, given the favorable safety profile of  this approach. A conceivable therapeutic option in the future could 
be to first treat patients with a gene-editing approach and subsequently supplement with lower doses of  
oligomers in order to maximize any therapeutic effect by targeting alleles that may have escaped genomic 
correction. As the field of  CRISPR research investigates potentially safer and more effective technologies 
for clinical translation, a promising approach our lab is currently pursuing is DNA base editing of  the 
+189C>T mutation to restore normal splicing in the defective allele, with no double-stranded breaks and a 
template-free approach to achieve precise single-nucleotide mutations with a single gRNA (58).
Important questions remain to be addressed on the path to clinical translation. For instance, it is 
unclear whether a therapeutic oligomer can reach its target interstitial cell in diseased and potentially 
fibrotic muscles, and if  so, whether reducing the mutational load could promote extracellular matrix 
remodeling after an abnormal matrix is already established, and finally, whether such remodeling could 
slow or reverse a decline in muscle function. In order to help answer these questions, an animal model 
is needed. The lack of  homology between the human COL6A1 intron 11 and the corresponding mouse 
Col6a1 intron 11 precludes the mere introduction of  the mutation in the mouse, a situation that could be 
circumvented by humanizing the relevant part of  the Col6a1 locus. Such a preclinical model would allow 
the targeting, skipping efficiency, and biological effect of  human-ready antisense oligomers to be assessed 
in vivo, while also providing insights into the molecular pathogenesis as a consequence of  this mutation.
In conclusion, we show that the identification of  an unexpectedly common pseudoexon-activating 
deep intronic mutation by advanced next-generation sequencing–based technologies directly resulted in 
the development of  rationally targeted therapeutic strategies. This, together with the even stronger ratio-
nale for dominant pseudoexon-inducing mutations such as the COL6A1 +189C>T mutation and the 
in-patient cell efficacy data shown here, supports the feasibility of  an accelerated translational path. In a 
broader context we have shown that combining RNA sequencing and whole-genome sequencing as diag-
nostic tools allows splice-altering mutations to be discovered at a surprisingly high frequency in previ-
ously undiagnosed patients (22). Many of  these mutations would be amenable to a precision therapeutic 
strategy using individualized splice-modulating approaches. Our experience thus argues for wider use of  
these diagnostic tools and the development of  a toolbox of  class-approved therapeutic reagents that can 
be used to treat splice mutations rapidly, even at the single-patient level.
Methods
Human subjects. Subjects were recruited at the NIH through the Pediatric Neuromuscular Clinic (12-N-0095 
approved by the Institutional Review Board of  the National Institute of  Neurological Disorders and Stroke 
[NINDS], NIH). Subjects were also identified through their local medical centers in Canada, Chile, Ger-
many, Ireland, Latvia, Romania, UK, France, Italy, Australia, Spain, and Israel. Complete clinical assess-
ment was performed by trained clinicians. Peripheral blood, skin biopsies, and muscle biopsy samples were 
obtained based on standard procedures.
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Diagnostic work-up and genetic testing. Diagnostic work-up included histological and immunofluores-
cence staining of  muscle biopsy sections, assessment of  collagen VI matrix deposition by cultured der-
mal fibroblasts, and cDNA sequencing of  the triple helical domains for the 3 main collagen VI genes 
(COL6A1, COL6A2, and COL6A3). Genomic DNA isolated from peripheral blood was used to screen for 
the COL6A1 +189C>T mutation by targeted amplification and sequencing (with primers listed in Supple-
mental Table 4). PCR products were sent to Genewiz for Sanger sequencing.
RNA sequencing and PSI. RNA sequencing of  muscle RNA from 4 patients (UK1, UK2, US1, and 
US2) was described in Cummings et al. (22). To compare the rate of  inclusion of  the intronic splice event 
in COL6A1 in muscle and fibroblasts, we performed paired-end 76-bp sequencing on Illumina HiSeq 2000 
instruments, with 50M sequence coverage for an RNA sample isolated from cultured skin fibroblasts 
(UK1). RNA sequencing data were aligned using Star 2-Pass version v.2.4.2a using hg19 as the genome 
reference and Gencode V19 annotations. We obtained inclusion of  values for the intronic splice-gain 
event in samples as described in Schafer et al. (50).
Cloning. Cloning for dual gRNAs was performed in a dual-guide expression pDG458 plasmid 
(pDG458 was a gift from Paul Thomas, University of  Adelaide, Adelaide, Australia; Addgene plas-
mid 100900). The selected gRNA sequences U1 and D1 were subcloned into the plasmid according 
to a pDG 1-step cloning protocol (59). Briefly, the guide sequences for upstream and downstream 
gRNA sequences were phosphorylated and annealed by mixing 100 pmol of  each pair and 0.5 μl T4 
PNK (NEB) and then incubated at 37°C for 30 minutes, followed by 95°C for 5 minutes, and slowly 
ramped to room temperature. Annealed oligos were diluted 1:125. Pairs of  oligo duplexes were 
ligated into empty vectors in a 1-step digestion ligation reaction described previously (59). Plasmid 
DNA was isolated using an endotoxin-free maxiprep kit (Qiagen) and correct insertion of  oligonu-
cleotide duplexes into the vectors was confirmed using the sequencing primers U6 and BGH PA F 
(Supplemental Table 4). The upstream and downstream gRNA sequences were scored and selected 
using crispr.mit.edu. The sequences of  the oligonucleotides used for cloning into the dual gRNA 
expressing SpCas9 plasmid are listed in Supplemental Table 4.
For additional cloning methods, see supplemental material.
Antisense oligomers. PMOs were designed following previously published guidelines (52) (Supplemen-
tal Table 3), and were purchased from GeneTools, LLC. For PMO-PEX3 and PMO-PEX4, mispairs 
(lower cases in the sequence) were voluntary introduced to reduce the G content and self-complementar-
ity (Supplemental Table 3). PMOs were reconstituted to a 1 mM stock solution in water.
2′OMe antisense oligomers were synthesized at Murdoch University, using phosphorothioate bonds 
and 2′OMe-modified RNA analogs (Supplemental Table 3). In 2′OMe-PEX2, one mismatch was intro-
duced (indicated in lower case, Supplemental Table 3).
Cell culture, transfection, nucleofection of  Cas9 plasmids, and oligomer treatment. Dermal fibroblasts 
from normal controls and patients were established from skin biopsies. HEK293T cells were obtained 
from ATCC. All cell lines were routinely maintained in Dulbecco’s modified Eagle medium (Gibco/
ThermoFisher Scientific) supplemented with 10% fetal bovine serum (FBS) (Corning/ThermoFisher 
Scientific) and 1% penicillin/streptomycin (Gibco/ThermoFisher Scientific) at 37°C in 5% CO2. 
At revival, cells were tested for mycoplasma contamination (MycoAlert mycoplasma detection kit, 
Lonza), and treated with MycoZap Reagent (Lonza) if  found positive. Experiments were conducted 
on mycoplasma-negative cells.
Minigene plasmids (0.2 μg) were complexed with 1.5 μl of  Lipofectamine 2000 or 3000 (Invitro-
gen/ThermoFisher Scientific) in OptiMEM (Invitrogen/ThermoFisher Scientific) and transfected into 
HEK293T cells in 500 μl of  DMEM supplemented with 10% FBS, in 24-well plates. Cells were then 
incubated for 24 hours before RNA isolation.
Antisense oligomer treatments were carried out in 24-well plates. Patient-derived skin fibroblasts 
(3 × 104 cells) were seeded in each well. The next day, cells were washed once with DMEM, then fresh 
medium (either 300 μl of  DMEM supplemented with 10% FBS for PMO transfection, or 200 μl of  
DMEM for 2′OMe oligomer transfection) was added to each well. For PMOs, the oligomer solutions 
were added to each well according to the desired final concentration, and the plate was gently swirled 
after each oligomer addition. Then, 2.6 μl of  Endo-Porter (GeneTools) was added directly to each well, 
and the plate was vigorously swirled after each addition. Cells were incubated for 48 hours before RNA 
isolation. For 2′OMe oligomers, the oligomers were complexed with 1.5 μl of  Oligofectamine (Invitro-
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gen/ThermoFisher Scientific) in OptiMEM according to the desired final concentration, and 50 μl of  
the complex was added to each well. Five hours later, 125 μl of  DMEM supplemented with 30% FBS 
was added to each well. Cells were incubated for 48 hours before RNA isolation.
For the antisense oligomer screen with the minigene system, HEK293T cells were incubated for 6 hours 
with the minigene DNA transfection mix. Cells were then washed once with DMEM, and the oligomer 
transfection was performed as described above. Cells were incubated for 48 hours before RNA isolation.
To determine Cas9 cutting efficiency, 1 × 105 of  HEK293T cells were plated overnight into 6-well 
plates and the following day, 5 μg of  Cas9 or Cas9+U1D1 was transfected using Lipofectamine 2000 (Invi-
trogen/ThermoFisher Scientific). Forty-eight hours after transfection, GFP enrichment was performed to 
harvest 2 × 105 cells that were processed for genomic DNA analysis. For the CRISPR/Cas9 experiments 
with minigene reporter assays, 5 μg of  plasmid, either Cas9 only or Cas9+U1D1, was cotransfected with 
1 μg of  the minigene splicing reporter constructs. Forty-eight hours after transfection, cells were harvested 
in TRIzol (Ambion/ThermoFisher Scientific) for RNA isolation and RT-PCR analyses. Nucleofection of  
patient dermal fibroblast cells was performed as follows: 2 × 106 cells were diluted in P2 buffer (Lonza), 
mixed with either 5 μg or 10 μg of  Cas9- or Cas9+U1D1–expressing plasmids, transferred to a cuvette, and 
subjected to the nucleofection program DT-130 (Lonza Amaxa 4D-nucleofector). After nucleofection, cells 
were allowed to sit for 10 minutes in the cuvette before pipetting the cells into 6-well plates for recovery. 
Forty-eight hours after nucleofection, cells were GFP-enriched and 1 × 105 cells were harvested for down-
stream analyses such as genomic DNA extraction, RNA extraction, and Western blotting.
RNA isolation and RT. Total RNA was isolated from muscle biopsy sections, or PBS-washed adherent 
cultured cells, using TRIzol. RNA (250 ng to 1 μg) was treated with 1 U of  rDNase I using the DNA-free 
kit (Ambion/ThermoFisher Scientific). cDNA was synthesized with SuperScript III Reverse Transcrip-
tase (Invitrogen/ThermoFisher Scientific), using the vector-specific primer 5′-ACTGATCCACGAT-
GC-3′ (for minigene-transfected cell samples), or random primers (Invitrogen/ThermoFisher Scientific). 
For minigene-transfected samples, cDNA was quantified with Quant-iT Oligreen ssDNA (Invitrogen/
ThermoFisher Scientific) and diluted to 5 ng/μl before amplification.
Quantitative PCR amplification. The quantitative PCR (qPCR) primer/probe mix to detect pseudoexon-in-
cluded transcripts was purchased as a PrimeTime qPCR Assay (Integrated DNA Technologies; Supplemental 
Table 4). To measure total COL6A1 expression or the endogenous control gene phosphoglycerate kinase 1 
(PGK1, Supplemental Table 4), the hydrolysis probes were purchased from the Universal Probe Library (UPL, 
Roche Applied Science). qPCR reactions were performed in a total volume of 10 μl, with 3 μl of cDNA 
and a 1× final concentration of the FastStart Master mix (containing ROX) (Roche Applied Science). The 
PrimeTime primers/probe mix was used at a 1× final concentration, while the UPL probe was used at 0.4 
μM, with primers at 0.7 μM each. qPCR reactions were run in quadruplicate, at 50°C for 2 minutes, 95°C for 
10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute, on the QuantStudio 6 Flex 
Real-Time PCR System (Applied Biosystems/ThermoFisher Scientific). Ct values were determined by the 
QuantStudio Real-Time PCR software (Applied Biosystems/ThermoFisher Scientific). The comparative Ct 
(ΔΔCt) method was applied to measure the relative expression, using the PGK1 Ct values as the endogenous 
normalizing gene, and the ΔCt values from the untreated controls as the normalizing value.
Methods for routine PCR and sequencing can be found in supplemental material.
Matrix immunofluorescence. Patient-derived skin fibroblasts were seeded (1.5 × 104 cells per well) in 
8-chamber tissue culture slides (Corning/ThermoFisher Scientific). The next day, medium was replaced 
with complete medium, supplemented with 50 μg/ml of  L-ascorbic acid (Wako Chemicals). Two days 
later, medium was replaced to provide a fresh supply of  L-ascorbic acid. The following day (3 days of  
L-ascorbic acid treatment), cells were washed in PBS once, then fixed in 4% paraformaldehyde (Electron 
Microscopy Sciences) for 10 minutes at room temperature. For antisense oligomer treatment followed by 
matrix staining, the same procedure was applied with these modifications: 0.7 × 104 cells per well were 
seeded, medium was replaced the next day to supplement with antisense oligomers (as described above), 
2 days later medium was replenished with fresh supply of  antisense oligomers and L-ascorbic acid, 2 
days later fresh L-ascorbic acid was added to the wells, and cells were fixed 3 days after L-ascorbic acid 
treatment (5 days after oligomer treatment).
For staining, cells were washed in PBS, then blocked for 1 hour with 10% FBS in PBS, with or with-
out 0.1% Triton X-100 (MilliporeSigma). Primary antibodies were diluted in the blocking buffer and 
applied to samples for 3 hours at room temperature. Samples were washed 3 times for 5 minutes with 
1 6insight.jci.org   https://doi.org/10.1172/jci.insight.124403
R E S E A R C H  A R T I C L E
PBS, and incubated with secondary antibodies, diluted in blocking buffer, for 1 hour at room tempera-
ture. Samples were again washed with PBS 3 times for 5 minutes each and incubated with 4′,6-diamid-
ino-2-phenylindole, dihydrochloride (DAPI) diluted in PBS, for 15 minutes. Samples were washed with 
PBS twice, and mounted with Fluoromount-G (SouthernBiotech). Antibodies used were as follows: 
mouse anti–human collagen VI (MAB1944, clone 3C4, MilliporeSigma); rabbit anti-fibronectin (F3648, 
MilliporeSigma); goat anti-mouse IgG, Alexa Fluor 488 (A-11001, Invitrogen/ThermoFisher Scientific); 
and goat anti–rabbit IgG, Alexa Fluor 568 (A-11036, Invitrogen/ThermoFisher Scientific).
Confocal microscopy. Images were acquired on a TCS SP5 II system (Leica Microsystems), with ×40 
or ×63 objectives. The pinhole was adjusted to obtain a section thickness of  0.508 μm, and Z-stacks were 
acquired using 0.5-μm-sized steps. Stacks were merged.
Pseudoexon-specific antibody. A polyclonal antibody was raised against the mutant peptide as follows. The 
peptide with sequence (TRSTAPRRPLHLEGQGQPPRHPAK-C) was synthesized (Pineda Antikörper-Ser-
vice) and disulfide linked via the C-terminal cysteine to keyhole limpet hemocyanin (KLH). The conjugate 
was used for immunization of a rabbit and antibodies raised in the serum harvested at 60 days after injection.
Immunoblotting. Patient-derived skin fibroblasts were treated with antisense oligomers in 24-well plates as 
described above but were incubated for a total of 4 days in the presence of the oligomers. Twenty-four hours 
after the start of oligomer treatment, L-ascorbic acid was added to each well for a final concentration of 50 
μg/ml. Four days after the start of oligomer treatment, medium was collected in a prechilled 1.5-ml tube, con-
taining a final 1× concentration of Complete Protease Inhibitor cocktail (Roche Applied Science), then was 
spun for 10 minutes at 15,000 g at 4°C, and supernatant was collected. The cell layer was washed twice with 
cold PBS and lysed with RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 
0.1% SDS, 1% NP-40) containing 1× Complete Protease Inhibitor cocktail. Samples were incubated on ice 
for 30 minutes, then spun for 20 minutes at 15,000 g at 4°C, and supernatant was collected. Protein concen-
trations were determined using BCA protein assay (ThermoFisher Scientific). Protein samples were diluted in 
NuPAGE LDS Sample Buffer (final concentration 1×; ThermoFisher Scientific), with 5% 2-mercaptoethanol 
(MP Biomedicals), boiled for 5 minutes at 95°C, and vortexed. Denatured protein samples (5 μg for cell lysates 
[or cellular fraction], 15 μg for medium [or secreted fraction]) were loaded onto a NuPAGE 4%–12% Bis-Tris 
gel (ThermoFisher Scientific), and run with 1× NuPAGE MOPS SDS Running buffer (ThermoFisher Scien-
tific) for 50 minutes at 200 V. Samples were transferred onto Immobilon-P PVDF membranes (MilliporeSig-
ma) using 1× NuPAGE Transfer buffer containing 5% methanol, for 1.5 hours at 25 V. Membranes were 
blocked with 5% milk in TBS containing 0.05% Tween-20 (TBS-T) (MilliporeSigma). Membranes were incu-
bated with primary antibodies diluted in blocking solution overnight at 4°C, followed by washing 3 times for 
5 minutes each with TBS-T. Membranes were then incubated with secondary antibodies in blocking solution 
for 2 hours at room temperature, followed by 3 times for 5 minutes each with TBS-T. When using HRP-linked 
secondary antibodies, chemiluminescence was detected using a Clarity Western ECL kit (Bio-Rad), and 
imaged on the ChemiDoc XRS+ Imaging System (Bio-Rad). For fluorescently labeled secondary antibod-
ies, membranes were imaged on the Odyssey CLx system (LI-COR Biosciences). The antibodies used were 
as follows: rabbit anti-pseudoexon (1:50 dilution); rabbit anti–collagen α1(VI) (1026, gift from Mon Li-Chu, 
Thomas Jefferson University, Philadelphia, USA; 1:7,500 dilution); mouse anti-tubulin, clone B-5-1-2 (T5168, 
MilliporeSigma, 1:6,000 dilution); anti–rabbit IgG, HRP-linked (Cell Signaling Technology, 1:1,000 dilution); 
anti–mouse IgG–HRP (PerkinElmer, 0.05 μg/ml); goat anti–rabbit IgG IRDye 680RD (LI-COR Biosciences, 
1:1,000 dilution); and goat anti–mouse IgG IRDye 800CW (LI-COR Biosciences, 1:1,000 dilution).
Negative-staining electron microscopy. Patient-derived skin fibroblasts (2.5 × 104 cells) were plated in single 
wells of 12-well plates. When cells reached approximately 60% confluence, antisense oligomer treatments 
were performed as described above. After 48 hours, medium was removed, and a second oligomer treatment 
was performed in the presence of L-ascorbic acid, as described above. After 48 hours (4 days after start of  
oligomer treatment), cells were washed twice with PBS, and then incubated in a small volume (250 μl) of  
DMEM supplemented with L-ascorbic acid (serum-free medium) for 16 hours. Medium was collected and 
supplemented with complete protease inhibitor cocktail (Roche Applied Science, 1× final concentration) and 
sodium azide (0.1% final concentration). Samples were spun at 15,000 g for 10 minutes at 10°C, and super-
natants were collected and stored at 4°C. Microfibrils were deposited on a carbon-coated electron microsco-
py grid, stained for 30 seconds with 1% aqueous uranyl acetate, blotted, and quickly air dried. Grids were 
observed at 300 kV using a Tecnai F30 (FEI) and micrographs were acquired with an Utrascan 1000 (Gatan). 
Grids were systematically scanned and 134–147 microfibrils were measured in each sample.
1 7insight.jci.org   https://doi.org/10.1172/jci.insight.124403
R E S E A R C H  A R T I C L E
Statistics. To compare collagen VI microfibrillar length, statistical significance between groups was 
assessed using Mann-Whitney U test, followed by Bonferroni’s correction for multiple comparisons. For the 
relative expression data (from the qPCR experiments), significance between groups was tested using repeat-
ed-measures 2-way ANOVA with Bonferroni’s correction. P values of  <0.05 were considered significant.
Study approval. This study was approved by the Institutional Review Board of  the National Institute 
of  Neurological Disorders and Stroke, NIH (12-N-0095). All subjects provided informed consent prior to 
participating in the study. Subjects were also identified through their local medical centers.
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